Calidi Q2 net loss narrows to $5.7M; FDA Fast Track for CLD-201; raises $4.6M

Calidi Biotherapeutics, Inc.

2025-Q2 EPS reported -$4.17

Net loss $5.7M ($1.99/share) vs $7.4M ($16.75/share) in Q2 2024; R&D $2.6M, G&A $3.1M.
Cash $5.3M at June 30, 2025, down from $9.6M at Dec 31, 2024; restricted cash $0.1M.
FDA Fast Track Designation granted for CLD-201 for soft tissue sarcoma; Phase 1 IND opened Q1 2025.
Raised $4.6M gross proceeds via warrant inducement; total 2025 raises $15.7M.
Preclinical data for CLD-401 (RedTail platform) presented at ASCO; IND expected by end 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.